InterCure Ltd.

NASDAQ:INCR

Drug Manufacturers - Specialty & Generic

Healthcare
$3.98 -3.97%

-$0.04 today

Market cap
$51.63M
Beta
0.57
P/E (TTM)
-4.3
EPS (TTM)
-$0.64
52W Low $0.68High $1.77

Volume 0.01M

Average 0.04M

INCR Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

InterCure Ltd.NASDAQ: INCR

Accounts Receivables · Q2 FY2025 · quarter ended Jun 2025

Accounts receivables turns positive

Q2 FY2025 accounts receivables was ₪2.47M, compared with -₪115K a year earlier. Trailing-twelve-month accounts receivables was ₪4.94M.

Context

  • Accounts receivables amounted to 3.4% of revenue in FY2025, down 2.1 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near ₪2.47M or moves back toward the trailing-twelve-month quarterly average of ₪1.24M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
₪2.47M+0.0% QoQ
Last fiscal yearDec 2025
₪9.29M-29.9% YoY
LTMJun 2025
₪4.94M+2249.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2249.6%——
1 year-29.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

ILS · from the cash flow

Latest · FY2025
9.29M ILS
Year-over-year change
-29.9%
4-year CAGR
+2.6%

Accounts Receivables vs competitors

How INCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2249.6% is the highest of 6, against a peer median of +120.1%.
  • Accounts receivables amounts to 2.0% of revenue for INCR, versus a peer median of 4.7%.
INCR Competitors
Accounts Receivables for INCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMWLAmerican Well CorporationLTM Mar 2026$9.9M USD+307.0%—4.2%
FBIOFortress Biotech, Inc.LTM Mar 2026$6.8M USD-23.8%+58.7%10.3%
INCRInterCure Ltd.LTM Jun 2025₪4.94M ILS+2249.6%—2.0%
ASRTAssertio Holdings, Inc.LTM Mar 2026$4.77M USD+120.1%+304.6%4.7%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$2.09M CAD-445.0%—11.4%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$6.69K CAD+227.1%——
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$0 USD——0.0%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
Peer median (excluding INCR) —+120.1%+181.6%4.7%

Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

ILS
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.3M43.75M(63.53M)(72.79M)(36.78M)
Depreciation & Amortization7.39M11.7M13.17M15.37M17.15M
Deferred Income Tax11.44M93K2.25M(14.53M)(7.32M)
Stock-Based Compensation6.45M8.91M2.59M2.28M2.43M
Change in Working Capital(1.65M)(3.02M)(43.55M)(9.19M)18.88M
Accounts Receivables8.39M(18.29M)(23.49M)13.26M9.29M
Inventory(17.89M)(75.99M)40.21M(17.44M)15.95M
Accounts Payables2.79M57.03M(47.63M)(8.9M)(8.82M)
Other Working Capital5.06M34.22M(12.63M)3.88M2.46M
Other Non-Cash Items(5.91M)(10.16M)35.44M11.94M22.49M
Operating Cash Flow25.02M51.27M(53.63M)(66.93M)16.84M
Capital Expenditures(14.03M)(19.74M)(2.62M)(4.38M)(3.55M)
Acquisitions (Net)(19.09M)(8.32M)(4.2M)405K1.67M
Purchases of Investments(1.25M)0000
Sales of Investments00000
Other Investing Activities(30.84M)(114.44M)11.59M21.66M(107K)
Investing Cash Flow(65.21M)(142.5M)4.77M17.69M(1.99M)
Debt Repayment65.83M137.73M(61.98M)7.74M(29.13M)
Common Stock Issued128.73M0034M1.5M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.38M(17.28M)(20.91M)(15.29M)(19.03M)
Financing Cash Flow197.94M120.45M(82.89M)26.46M(46.66M)
Effect of Forex Changes(4.54M)7.16M297K(39K)(44K)
Net Change in Cash158.33M36.37M(131.45M)(22.82M)(31.85M)
Free Cash Flow10.99M31.53M(56.25M)(71.3M)13.29M

InterCure Ltd.

NASDAQ:INCR

Intrinsic Alpha fair value

Locked

Current Price

$3.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.